Researchers test gene therapy targeting a different cancer protein in a new trial, the New York Times reports.
The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.
A biotech investor tells CNBC that gene therapies could treat a range of diseases.
UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.
The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.
Kaiser Health News reports that gene therapies could cost more than a million dollars.
The therapy treats a form of childhood blindness and, if approved, would be the first approved gene therapy in the US.
US Food and Drug Administration advisors are to weigh gene therapy for blindness, according to Reuters.
A new study suggests that gene therapy could help boys with the brain disease adrenoleukodystrophy, the New York Times reports.
While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.
Pennsylvania State University researchers found that salivary microRNAs could predict which kids would have longer concussion symptoms, according to NPR.
The Associated Press reports Alex Azar, the new Department of Health and Human Services secretary nominee, made millions of dollars as a pharmaceutical executive.
In PNAS this week: immune profiling of breast cancer, transposable element patterns in rice, and more.